Huaren Pharmaceutical Co., Ltd. (SHE:300110)

China · Delayed Price · Currency is CNY

2.960

+0.130 (4.59%)

Aug 20, 2026, 3:04 PM CST

-17.55% (1Y)

Market Cap	3.50B -17.1%
Revenue (ttm)	1.33B +6.2%
Net Income	-462.97M
EPS	-0.39
Shares Out	1.18B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,932,400
Open	2.830
Previous Close	2.830
Day's Range	2.830 - 3.020
52-Week Range	2.410 - 3.660
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Huaren Pharmaceutical

Huaren Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medicines and medical equipment in China and internationally. It offers nephrology products, including peritoneal dialysate, hemofiltration replacement fluid, and hemofiltration basic solution; respiratory products, such as doxofylline, levofloxacin hydrochloride, and composite potassium hydrogen phosphate injections; caffeine citrate injection; and bulk preparations comprising sodium chloride, glucose, glucose and sodi... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,549

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300110

Full Company Profile

Financial Performance

In 2025, Huaren Pharmaceutical's revenue was 1.32 billion, a decrease of -2.34% compared to the previous year's 1.35 billion. Losses were -462.90 million, -66.17% less than in 2024.

Financial Statements